EU Takes Focused Approach In Bid To Deliver Decentralized Clinical Trials Guide By Year End
Executive Summary
EU regulators are eager to roll out harmonized requirements for decentralized clinical trials by the end of 2022 and so have decided to tackle some of the notably trickier issues in greater detail later on.
You may also be interested in...
EU Regulators Urged To Address Impact Of Decentralized Trials On Data Quality & Integrity
The pharmaceutical industry has identified a range of statistical considerations relating to decentralized clinical trials that they want EU regulators to address to ensure data generated from such studies are acceptable for regulatory filings.
EU Countries Focus On National Best Practices For Decentralized Trial Approvals & Inspections
The EU recommendation paper on decentralized clinical trials (DCTs) marked an important “first step” on the direction the European regulatory network wants to take with DCTs. Member states are now focused on reviewing and tracking DCTs to gain experience before considering the need for any updates to the recommendation paper.
EU Aims To Drive Uptake In Decentralized Clinical Trials With Harmonized Guide
The highly anticipated pan-EU recommendation paper on decentralized clinical trials explains the factors that sponsors should consider when designing and implementing such trials.